nightclaude · nightly deep dive · 2026-10-17
Tubeless winner at $141.10: $2.71B sales, broken conversion
Insulet scaled Omnipod revenue to $2.71B in FY2025 with $1.94B of gross profit at 71.1% margin and $473.80M of operating income. At $141.10, down from a $354.88 high, the market values $9.79B of equity at 26.42 times trailing earnings after net income fell to $247.10M.
Insulet bet against the tube when Medtronic and Tandem perfected it, selling a disposable, wearable pod through the pharmacy channel instead of durable medical equipment. With 5400 employees in Acton, Massachusetts, it compounded revenues from $1.31B in FY2022 to $2.07B in FY2024 to $2.71B in FY2025, turning consumable refills into $1.94B of gross profit at 71.1% margin and $473.80M of operating income at 16.2% margin.
The tape refused to pay up. The stock closed at $141.10 against a $126.40 low and $354.88 high, down 55.4% in one year and 51.7% over five years, for a $9.79B market cap and $10.20B enterprise value at 18.27 times forward earnings and 16.59 times EV to EBITDA. Cash of $716.10M against $949.20M of total debt and $1.52B of equity leaves no second division to hide in when a single pod franchise must fund $301.10M of R and D and convert 23.5% growth into more than $247.10M of net income.
History & Ownership
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts, with 5,400 employees. The founding thesis was bluntly contrarian: while Medtronic and later Tandem Diabetes built better tubed pumps, Insulet would eliminate the tube entirely with a wearable, disposable pod. That choice defined its channel strategy as well. Where conventional pump makers lived in durable medical equipment distribution, Insulet pushed Omnipod through the pharmacy channel and independent distributors in the United States and internationally, a lower friction model that later became central to primary care and Type 2 expansion.
From startup pod to Omnipod 5 platform
The product arc runs from the original Omnipod Insulin Management System to Omnipod DASH, a Bluetooth enabled pod controlled by a smartphone-like personal diabetes manager with a color touch screen, to Omnipod 5, which embeds a proprietary automated insulin delivery algorithm in the pod itself and integrates with a third-party continuous glucose monitor over wireless Bluetooth. Insulet also supplies pods for Amgen for use in the Neulasta Onpro kit, a non diabetes drug delivery application that monetizes the same wearable injector competence.
Scale arrived in steps validated by SEC EDGAR annual XBRL facts. Revenues were $463.77M in FY2017, then $1.31B in FY2022, $1.70B in FY2023, $2.07B in FY2024 and $2.71B in FY2025. Operating income moved from $37.60M in FY2022 to $220.00M in FY2023, $308.90M in FY2024 and $473.80M in FY2025, while research and development rose from $180.20M to $301.10M over the same period. Net income traces the operating leverage and capital structure cleanup, from $4.60M in FY2022 to $206.30M in FY2023, $418.30M in FY2024 and $247.10M in FY2025. Balance sheet repair accompanied it. Total assets grew from $2.25B in FY2022 to $3.19B in FY2025, stockholders equity from $476.40M to $1.52B, while liabilities fell from $1.88B in FY2024 to $1.68B in FY2025. The company has no spin off history of consequence. It is a single thesis compounder that stayed public and reinvested, in contrast to Medtronic Diabetes which grew inside a conglomerate and Tandem which remained a narrower pump pure play.
Ownership: widely held, institutionally dominated
Insulet is a widely held large cap medical device stock, not a founder controlled company. Insiders hold 0.33%, institutions hold a reported 106.97% of outstanding shares and 107.32% of float across 1,085 institutions, the over 100% figure reflecting standard float accounting effects from lending and short positions rather than literal ownership. The implication is full institutional ownership with minimal insider block, so governance runs through the board and executive team, not a control shareholder.
| Measure | Level |
|---|---|
| Current price, Oct. 16, 2026 | $141.10 |
| Market cap and enterprise value | $9.79B and $10.20B |
| Cash and total debt, FY2025 | $716.10M and $949.20M, with $930.80M long term |
| Analyst target mean and recommendation | $167.17, buy |
The shareholder base has absorbed severe multiple compression. The stock closed at $141.10 against a 52 week range with a $126.40 low and $354.88 high, with a 1 year return of negative 55.4% and a 5 year return of negative 51.7%. That drawdown, set against trailing gross margin of 71.1%, operating margin of 16.2%, profit margin of 12.3%, return on equity of 26.0% and year over year revenue growth of 23.5%, explains both the turnover and the continued institutional presence: growth plus high gross margins, repriced on retention, competition with Tandem and Medtronic, and closed loop execution risk shared with CGM partners Dexcom and Abbott.
Management character: professional operators, commercial turn
Leadership is now firmly in professional manager hands. Ashley McEvoy was appointed President and Chief Executive Officer effective immediately, succeeding Jim Hollingshead who ceased employment and resigned from the board, per investors.insulet.com, April 2025. Mike Panos was appointed Executive Vice President and Chief Commercial Officer effective March 30, 2026, reporting to McEvoy, per simplywall.st, June 2026. Jonathan Mazelsky joined the board effective July 1, 2026, followed by the September 2026 departures of longtime directors Timothy Scannell and Michael Minogue, per simplywall.st, October 2026. The character signal is commercial execution over inventor stewardship: pharmacy channel scale, payer contracting, international rollout and onboarding and retention discipline, the same operating challenges that separate Insulet from engineering led Tandem and procedure led diversified device peers.
Business Model & Strategy
Insulet Corporation, headquartered in Acton, Massachusetts and employing 5,400 people, is a pure play tubeless insulin pump company built around a single franchise: Omnipod. The economic story is scale on a disposable. Revenue rose from $1.31B in FY2022 to $1.70B in FY2023 to $2.07B in FY2024 to $2.71B in FY2025, while operating income rose from $37.60M to $473.80M over the same period. That operating leverage, paired with a 71.1% gross margin and 16.2% operating margin, is the engine. At $141.10, the market values that engine at $9.79B in market capitalization and $10.20B in enterprise value.
What it sells and to whom
Insulet sells wearable, tubeless pods that deliver insulin continuously, controlled wirelessly rather than through tubing and a separate pump body. Customers are people with insulin dependent diabetes in the United States and internationally, accessed through prescribers, payers, and distributors, not hospitals.
- Omnipod 5: automated insulin delivery system with a proprietary algorithm embedded in the pod itself, integrating via wireless Bluetooth with third party continuous glucose monitors to adjust insulin from glucose values.
- Omnipod DASH and Omnipod Insulin Management System: Bluetooth enabled pod controlled by a smartphone like personal diabetes manager with a color touch screen, the bridge products that built the tubeless installed base before automation.
- Drug Delivery: pods supplied to Amgen for use in the Neulasta Onpro kit to reduce infection risk after intense chemotherapy, a small non diabetes tail.
Distribution is the quiet moat. Insulet sells to end users through the pharmacy channel and through independent distributors, letting patients pick up pods with a pharmacy benefit rather than navigating durable medical equipment billing. That pharmacy access, described as a significant competitive moat (per markets.financialcontent.com, February 2026), lowers friction for new starts versus tubed rivals Medtronic MiniMed 780G and Tandem t:slim X2 with Control-IQ, which remain tethered architectures, while even Tandem Mobi still uses a short infusion set with tubing.
Recurring versus one time economics
There is almost no one time hardware sale here. The pod is a consumable, worn for days then discarded and replaced, which turns each new patient start into an annuity-like stream of repeat pod shipments and resupply reorders. Controllers and apps are enablers, pods are the revenue. That is visible in the Q2 2026 mix, when Total Omnipod revenue was $795.9M of $801.7M in total revenue, with $544.1M from U.S. Omnipod and $251.8M from International Omnipod (per investors.insulet.com, August 2026). Drug Delivery was just $3.3M in Q1 2026 (per sec.gov, May 2026). Retention, payer reauthorization, and continuous glucose monitor pairing therefore matter more than quarterly box placements.
| FY engine, SEC EDGAR | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenues | $1.70B | $2.07B | $2.71B |
| Operating income | $220.00M | $308.90M | $473.80M |
| Net income | $206.30M | $418.30M | $247.10M |
| R and D expense | $205.00M | $219.60M | $301.10M |
Strategy and flywheel
Strategy is to make tubeless the default and automation the lock in. Insulet invests the consumable gross profit back into algorithm, Bluetooth integration with Dexcom and Abbott sensors, smaller pods, phone control, and manufacturing productivity, then uses easier starts through pharmacy to add users, scale factories, and expand margin. R and D rose to $301.10M in FY2025, while adjusted operating margin expanded by 140 basis points year over year in Q2 2026 on manufacturing productivity and scale (per finance.yahoo.com, October 2026). The automated insulin delivery market is now a tight oligopoly dominated by Medtronic, Insulet and Tandem (per flash.stocksentinel.ai, August 2026), but Insulet outgrew tracked peers 23.5% to 8.5% in Q2 2026 while holding a 12.3% profit margin on a $3.19B asset base with $716.10M in cash against $949.20M in total debt (per csimarket.com, October 2026). More users fund more automation, more automation defends the pod annuity, and pharmacy scale makes the next prescriber conversion cheaper than the last.
Segments & Products
Insulet is a tubeless patch pump pure play built around one franchise, Omnipod, sold to people with insulin dependent diabetes in the United States and internationally. The company reported Revenues of $2.71B in FY2025, up from $2.07B in FY2024 and $1.31B in FY2022, with Gross Profit of $1.94B and Operating Income of $473.80M in FY2025. That scale comes from 5,400 employees in Acton, Massachusetts supporting a disposable pod model, not a diversified device portfolio.
Product mix: Omnipod is the company
The platform has three commercial iterations. Omnipod 5 is the automated insulin delivery system, with a proprietary AID algorithm embedded in the pod itself that pulls glucose values from a third party continuous glucose monitor over Bluetooth. Omnipod DASH is the prior Bluetooth enabled pod controlled by a smartphone like personal diabetes manager with a color touch screen. The legacy Omnipod Insulin Management System remains in the lineup. Insulet also makes pods for Amgen for use in the Neulasta Onpro kit, a non diabetes drug delivery application.
Economically, Omnipod is effectively all of sales. Total Omnipod revenue was $795.9M against total company revenue of $801.7M in the second quarter, per investors.insulet.com, Aug 2026, with U.S. Omnipod revenue of $544.1M and International Omnipod revenue of $251.8M in that quarter. Drug Delivery was $3.3M in the first quarter, per sec.gov, May 2026. There is no meaningful second segment to underwrite.
| Omnipod scale proxy | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenues | $1.31B | $1.70B | $2.07B | $2.71B |
| Gross Profit | $805.60M | $1.16B | $1.45B | $1.94B |
| Operating Income | $37.60M | $220.00M | $308.90M | $473.80M |
End markets: pharmacy channel, Type 1 core, Type 2 option
Insulet sells to end users through the pharmacy channel and through independent distributors, a critical distinction from Medtronic MiniMed and Tandem t:slim X2 tubed pumps that historically leaned on durable medical equipment adjudication. Pharmacy access shortens the prescription to pod fill cycle, supports the razor and blade refill stream, and widens primary care reach beyond endocrinology clinics.
The core is Type 1 diabetes, where automated delivery plus Dexcom or Abbott sensors is now standard of care. The expansion vector is insulin intensive Type 2, including basal only and multiple daily injection switchers who will not accept tubing. International is the second leg, with Omnipod 5 availability in 19 countries after launches in five Middle East countries, per investors.insulet.com, May 2026. That quarter, International Omnipod grew 59.4% year over year on a reported basis, per sec.gov, May 2026, off a smaller installed base than the U.S.
Pricing power: disposables at medtech margins
Gross margin was 71.1%, operating margin was 16.2% and profit margin was 12.3%, with a current price of $141.10 and market cap of $9.79B. The pod is a high gross margin consumable, replaced every three days, so pricing sticks through volume and mix rather than upfront hardware discounts. Management cited favorable price mix in the second quarter alongside manufacturing productivity and scale benefits, per finance.yahoo.com, Aug 2026, with adjusted operating margin up 140 basis points year over year.
That is the moat versus tubed rivals. Medtronic sells an integrated pump plus sensor system anchored by hardware, Tandem sells the t:slim X2 platform plus software upgrades. Insulet sells adherence. Tubeless wearability, phone control, and CGM choice reduce churn, which funds R and D of $301.10M in FY2025 without destroying the P and L.
Growth drivers
- Omnipod 5 algorithm and sensor choice: a new algorithm update adds a 100 mg/dL target setting and fewer exits from automated mode during prolonged highs, per investors.insulet.com, May 2026, plus a U.S. limited release with FreeStyle Libre 3 Plus to sit alongside Dexcom G7 compatibility.
- Type 2 penetration: a no tubing, pharmacy fulfilled AID system converts injection users who reject tubed pumps, the largest addressable pool in insulin delivery.
- International reimbursement: country by country Omnipod 5 coverage in Europe, Australia and the Middle East extends the U.S. playbook at higher growth rates.
- Fully closed loop pipeline: Insulet is developing an Omnipod 6 and a Type 2 fully closed loop system with no bolus button and automated titration, described as completely different from MiniMed and Tandem approaches, per medtechdive.com, June 2026.
Operations & Go-to-Market
Insulet is a single platform operator, not a diversified device conglomerate. The company develops, manufactures, and sells insulin delivery systems for insulin dependent diabetes in the United States and internationally, from headquarters in Acton, Massachusetts, with 5400 employees supporting $2.71B of FY2025 revenue on SEC EDGAR facts. That focus explains the operating leverage: FY2025 operating income of $473.80M on that $2.71B base, with gross margin of 71.1% and operating margin of 16.2%, a profile that looks more like a razor and blade consumable than a capital equipment pump business.
Manufacturing footprint and vertical integration
Insulet owns the pod and the algorithm, not the sensor. The Omnipod 5 system embeds a proprietary automated insulin delivery algorithm directly in the wearable pod, which then pulls glucose values from a third party continuous glucose monitor over wireless Bluetooth. That architecture is deliberately semi integrated. Insulet controls the disposable pod, the highest volume and highest gross profit element at $1.94B of gross profit in FY2025, while outsourcing glucose sensing to Dexcom and Abbott style CGM partners. Contrast that with Medtronic, which pushes a closed loop of its own pump plus its own Guardian sensor, and Tandem, which historically leaned on Dexcom integration with a rechargeable tubed pump. Insulet spent $301.10M on research and development in FY2025 and $219.40M on capital expenditure, funded by $569.30M of operating cash flow, a reinvestment cycle tied to pod capacity, automation, and algorithm iterations rather than a broad hospital salesforce. Total assets stood at $3.19B against total liabilities of $1.68B at FY2025 year end, with cash and cash equivalents of $716.10M. A manufacturing quality overhang remains operationally relevant, with a voluntary correction of certain pods across Omnipod lines for a potential under delivery issue discussed around August 2026, per reuters.com, August 2026.
Distribution: pharmacy channel as weapon
Insulet sells to end users through the pharmacy channel and through independent distributors. The pharmacy route is the go to market edge. Traditional tubed pumps from Medtronic and Tandem historically moved through durable medical equipment adjudication, with high upfront costs, prior authorizations, and multi year lock in. Omnipod, as a disposable pod replaced every three days, clears like a prescription benefit, lowering the friction for a new start and for a primary care prescription. Scale of that prescriber engine showed in the second quarter call, with more than 32,000 U.S. healthcare providers prescribing Omnipod, up 27% year over year, per finance.yahoo.com, October 2026. The second leg is contract drug delivery. Insulet provides pods for Amgen for use in the Neulasta Onpro kit, a delivery system to reduce infection risk after intense chemotherapy, a small but fully manufactured revenue stream that monetizes the same pod engineering outside diabetes.
| Platform | What it is operationally | How it is controlled |
|---|---|---|
| Omnipod 5 | Tubeless wearable pod with embedded AID algorithm, Bluetooth link to third party CGM | Automated insulin delivery |
| Omnipod DASH | Bluetooth enabled pod plus smartphone like manager | Color touchscreen personal diabetes manager |
| Omnipod Insulin Management System | Legacy tubeless pod system | Handheld control |
| Drug Delivery for Amgen Onpro | Pod supplied for Neulasta Onpro kit | Single use on body infusor |
Geographic exposure
The business is U.S. led with accelerating international pull. The pack discloses sales in the United States and internationally without a filed split, but the Q2 2026 print quantified the mix at $801.7 million of total revenue, comprising $795.9 million of total Omnipod revenue, with U.S. Omnipod at $544.1 million and international Omnipod at $251.8 million, per investors.insulet.com, August 2026. Management flagged Omnipod 5 as the number one pump for new users in Australia and cited a recent launch in Spain, per finance.yahoo.com, October 2026. That matters because international tubeless penetration lags the U.S., leaving Insulet competing less against entrenched Medtronic DME contracts and more against out of pocket tubed pump habits, where pharmacy simplicity and a tubeless form factor carry disproportionate weight.
Financials
Insulet closed at $141.10 on Oct 16, 2026 (per yfinance), for a market cap of $9.79B and an enterprise value of $10.20B (per yfinance). The stock sits below its 52 week high of $354.88 and above its 52 week low of $126.40 (per yfinance), after a 1 year return of -55.4% and a 5 year return of -51.7% (per yfinance). The tape prices a growth compounder in a drawdown, at a trailing P/E of 26.42, a forward P/E of 18.27 and EV/EBITDA of 16.59 (per yfinance), versus a Street mean target of $167.17 and a buy recommendation (per yfinance).
Revenue trajectory
Revenue was $2.71B in FY2025, $2.07B in FY2024, $1.70B in FY2023 and $1.31B in FY2022 (per EDGAR). That is a doubling in three years, with yfinance still printing 23.5% year over year revenue growth (per yfinance). The longer ramp was $463.77M in FY2017, $1.10B in FY2021 on the contract revenue disclosure and $1.06B in FY2022 (per EDGAR), then the Omnipod 5 cycle lifted reported Revenues from $1.31B in FY2022 to $2.71B in FY2025 (per EDGAR). Momentum persisted into 2026, with second quarter revenue of $801.7M, up 23.5% year over year (per sec.gov, Aug 5, 2026). Management guided to 2026 total company revenue growth of 20% to 22% (per finance.yahoo.com, Oct 3, 2026).
Margins, EPS and returns
Gross profit was $1.94B in FY2025, $1.45B in FY2024, $1.16B in FY2023 and $805.60M in FY2022 (per yfinance), consistent with a 71.1% gross margin (per yfinance). Operating income was $473.80M in FY2025, $308.90M in FY2024, $220.00M in FY2023 and $37.60M in FY2022 (per EDGAR), consistent with a 16.2% operating margin (per yfinance). R and D rose to $301.10M in FY2025 from $219.60M in FY2024, $205.00M in FY2023 and $180.20M in FY2022 (per EDGAR). Net income was $247.10M in FY2025, $418.30M in FY2024, $206.30M in FY2023 and $4.60M in FY2022 (per EDGAR), for a 12.3% profit margin (per yfinance). Diluted EPS was $3.48 in FY2025, $5.78 in FY2024, $2.94 in FY2023 and $0.07 in FY2022 (per yfinance). EBITDA was $489.30M in FY2025, $423.70M in FY2024, $323.70M in FY2023 and $109.00M in FY2022 (per yfinance). Returns remain high, with ROE of 26.0% and ROA of 9.7% (per yfinance).
Balance sheet
Cash and cash equivalents were $716.10M in FY2025, $953.30M in FY2024, $704.20M in FY2023 and $674.20M in FY2022 (per yfinance). Total debt was $949.20M in FY2025, $1.38B in FY2024, $1.42B in FY2023 and $1.40B in FY2022 (per yfinance), with long term debt of $930.80M in FY2025, $1.30B in FY2024, $1.37B in FY2023 and $1.37B in FY2022 (per yfinance). Total assets were $3.19B in FY2025, $3.09B in FY2024, $2.59B in FY2023 and $2.25B in FY2022 (per EDGAR). Total liabilities were $1.68B in FY2025, $1.88B in FY2024, $1.86B in FY2023 and $1.77B in FY2022 (per EDGAR). Stockholders equity grew to $1.52B in FY2025 from $1.21B in FY2024, $732.70M in FY2023 and $476.40M in FY2022 (per EDGAR), funding deleveraging while headcount reached 5400 (per yfinance).
Cash flow and capital allocation
Operating cash flow was $569.30M in FY2025, $430.20M in FY2024, $145.70M in FY2023 and $119.00M in FY2022 (per yfinance). Free cash flow was $349.90M in FY2025, $296.20M in FY2024, $36.50M in FY2023 and $-38.30M in FY2022 (per yfinance), with yfinance also showing TTM free cash flow of $236.90M (per yfinance). Capital expenditure was $219.40M in FY2025, $134.00M in FY2024, $109.20M in FY2023 and $157.30M in FY2022 (per yfinance). Allocation is reinvestment first, with repurchase of capital stock of $59.60M in FY2025 and $0.00 in FY2024 and FY2023 (per yfinance) and no dividend disclosed in the pack.
| Metric, per EDGAR except FCF, EPS and Gross profit per yfinance | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.31B | $1.70B | $2.07B | $2.71B |
| Gross profit | $805.60M | $1.16B | $1.45B | $1.94B |
| Operating income | $37.60M | $220.00M | $308.90M | $473.80M |
| Net income | $4.60M | $206.30M | $418.30M | $247.10M |
| Diluted EPS | $0.07 | $2.94 | $5.78 | $3.48 |
| Free cash flow | $-38.30M | $36.50M | $296.20M | $349.90M |
Revenue & net income by fiscal year ($B)
Margin trend by fiscal year
Competitive Landscape & Moat
Insulet at $141.10, with a $9.79B market cap and $10.20B enterprise value, is the pure play on tubeless insulin delivery in a market still defined by tubes. SEC EDGAR puts 10-K revenues at $1.31B in FY2022, $1.70B in FY2023, $2.07B in FY2024 and $2.71B in FY2025, with gross profit of $1.94B and operating income of $473.80M in FY2025. That scale, at a 71.1% gross margin and 16.2% operating margin, funds $301.10M of R and D and supports a $716.10M cash balance against $949.20M of total debt and $1.52B of equity. The stock has collapsed from a $354.88 52-week high to $141.10, down 55.4% over one year, pricing Insulet at 26.42 times trailing earnings, 18.27 times forward earnings and 16.59 times EV to EBITDA against a $167.17 consensus target that still reads buy.
Two architectures, three named rivals
The U.S. and European automated insulin delivery market is split between tethered durable pumps and patch pumps. Medtronic, with the MiniMed 780G, is the installed base gorilla, with an integrated Guardian CGM, entrenched endocrinology contracts and hospital presence. Per gminsights.com, August 2026, Medtronic held over 25% of the global pump market in 2025 in a $6.6B market estimated at $7.4B in 2026. Tandem Diabetes Care, with the t:slim X2 paired to Dexcom, is the technology peer, selling the smallest durable touchscreen pump and Control-IQ automation. Roche Accu-Chek and Ypsomed YpsoPump divide much of the European tethered remainder, while the low end competitor is not a pump at all but multiple daily injections with pens from Novo Nordisk, Eli Lilly and Sanofi.
Insulet owns the other architecture almost alone. Per marketintelo.com, July 2025, patch pumps were about 31% of new pump initiations in 2025 versus about 15% in 2018, and Omnipod held about 82% of that patch category. That is the moat in one sentence: Medtronic owns tethered, Insulet owns tubeless. Omnipod 5 embeds its SmartAdjust AID algorithm in the pod itself, integrates by Bluetooth to a third party CGM, is waterproof and worn for up to 72 hours with no tubing and no separate durable controller to carry. Omnipod DASH kept the same idea for non automated users with a Bluetooth pod plus smartphone like personal diabetes manager. No scaled rival offers that form factor, which explains the growth split disclosed per sec.gov, August 2026: second quarter 2026 revenue of $801.7M, up 23.5%, with U.S. Omnipod of $544.1M, up 20.1%, and International Omnipod of $251.8M, up 35.5%.
Where Insulet leads, where it lags
- Form factor and pharmacy channel: Tubeless discretion, freedom for kids and active adults, and dispensing through the pharmacy rather than durable medical equipment shortens onboarding and widens primary care reach. That is why International, now in 19 countries after a five country Middle East launch per sec.gov, May 2026, is growing faster than the U.S.
- Consumable flywheel: Every starter kit creates a recurring pod annuity at 71.1% gross margin. Operating cash flow was $569.30M in FY2025 against $219.40M of capex, and scale manufacturing in Acton and Malaysia drives operating margin expansion.
- Lags in ecosystem control: Insulet does not own the sensor. It borrows accuracy and innovation cycles from Dexcom and Abbott, while Medtronic bundles pump plus CGM and Tandem rides Dexcom G7 loyalty. High total daily dose Type 1s and price sensitive Type 2s still favor a 300 unit t:slim reservoir or cheap pens over changing a pod every three days.
- Type 2 retention: Management flagged weak 90 day retention and utilization in the Type 2 cohort on the Q2 call, summarized per simplywall.st, October 2026, and trimmed U.S. Omnipod guidance even as international guidance rose to 30% to 32% growth. Per quiverquant.com, October 2026, Jefferies cut its target to $190 from $275 while keeping a Buy, a direct read on physician love for the product versus payer and persistence risk.
What is actually durable
The moat is not a patent alone, it is switching cost stacked on habit. An Omnipod 5 start requires prescriber training, prior authorization through pharmacy benefit managers, CGM pairing, and weeks of algorithm personalization. Once basal rates, carb ratios and activity modes are tuned, neither patient nor endocrinologist wants to restart on a tubed pump. The installed base of 5,400 employee supported users, distributors and pharmacy contracts then compounds, plus a small but sticky Drug Delivery line making pods for Amgen Neulasta Onpro. Regulation reinforces it: FDA clearance for interoperable AID, Bluetooth coexistence, and iterative SmartAdjust claims take years for EOPatch, Kaleido or TouchCare copycats to replicate at Insulet yields. Scale does the rest. At $2.71B of revenue, 12.3% profit margin, 26.0% ROE and 9.7% ROA, Insulet can outspend any patch startup on miniaturization, automation and payer evidence while Medtronic and Tandem defend tethered share they cannot abandon without cannibalizing their own durables.
Verdict & Valuation
Hold at $141.10. Do not buy this dip. Insulet compounded SEC EDGAR revenues from $1.31B in FY2022 to $1.70B in FY2023 to $2.07B in FY2024 to $2.71B in FY2025, with gross profit of $1.94B in 2025 at 71.1% gross margin and operating income of $473.80M in FY2025 versus $308.90M in FY2024 versus $220.00M in FY2023 versus $37.60M in FY2022. That is a genuine tubeless compounder, built on Omnipod 5 with a proprietary AID algorithm in the pod paired by Bluetooth to third party CGM, plus Omnipod DASH and the legacy system, sold through the pharmacy channel and distributors with 5400 employees from Acton, Massachusetts. The market still cut it from a 52 week high of $354.88 to a last close of $141.10 on 2026-10-16, just above the 52 week low of $126.40, for a 1 year return of negative 55.4% and a 5 year return of negative 51.7%. The cut was not wrong. Growth stopped converting.
Q2 2026 is the tell. Revenue was $801.70M, up 23.5% or 22.7% in constant currency, above the 20% to 22% constant currency guidance range, with total Omnipod revenue of $795.90M up 24.6%, U.S. Omnipod revenue of $544.10M up 20.1% and international Omnipod revenue of $251.80M up 35.5%, and operating income of $129.70M or 16.2% of revenue (per sec.gov, August 2026). Adjusted EPS was $1.66, up 41.5% (per finance.yahoo.com, August 2026). Management then cut the full year U.S. Omnipod outlook to 17% to 19% growth and set total company growth at 20% to 22% while raising international to 30% to 32%, explicitly to incorporate weaker utilization and retention in the Type 2 base (per finance.yahoo.com, August 2026). In other words, the beat was Type 1 and international, the guide cut was the future growth engine.
What $141.10 actually pays for
The pack prices Insulet at $9.79B market cap and $10.20B enterprise value, at 26.42 times trailing earnings, 18.27 times forward earnings and 16.59 times EV to EBITDA, with an analyst target mean of $167.17 and a buy recommendation. That forward multiple looks cheap for 23.5% revenue growth, 16.2% operating margin, 12.3% profit margin, 26.0% ROE and 9.7% ROA. It is not cheap once you see SEC EDGAR net income of $247.10M in FY2025 versus $418.30M in FY2024 versus $206.30M in FY2023, with diluted EPS of $3.48 versus $5.78 in FY2024. Gross margin of 71.1% produced EBITDA of $489.30M, operating cash flow of $569.30M and free cash flow of $349.90M versus $296.20M in 2024 versus $36.50M in 2023 versus negative $38.30M in 2022, but R and D jumped to $301.10M from $219.60M and the bottom line shrank while revenue rose from $2.07B to $2.71B. A 26.42 times trailing multiple on shrinking GAAP earnings, anchored by a $167.17 target that has not caught up to the retention warning, is a show me multiple, not a value multiple.
| Valuation anchor | Figure |
|---|---|
| Price versus range | $141.10 versus $354.88 high and $126.40 low |
| Capitalization | $9.79B market cap, $10.20B enterprise value |
| Multiples | 26.42 trailing P/E, 18.27 forward P/E, 16.59 EV/EBITDA |
| Street | $167.17 mean target, buy recommendation |
| Balance sheet | $716.10M cash versus $949.20M total debt, $1.52B equity on $3.19B assets |
Balance sheet repair is real but thin for a one form factor bet. Total debt fell to $949.20M from $1.38B in 2024, long term debt fell to $930.80M from $1.30B, equity rose to $1.52B from $1.21B in 2024 and $732.70M in 2023, liabilities fell to $1.68B from $1.88B on assets of $3.19B. Cash fell to $716.10M from $953.30M while capital expenditure rose to $219.40M, leaving that $349.90M of free cash flow to fund pods, capacity and that $301.10M R and D bill. Repurchase of capital stock was only $59.60M. That self funds growth if pods stick. If Type 2 churns, there is no second division to hide in, unlike Medtronic or Abbott. Insulet is Omnipod 5, DASH and legacy pods, plus Amgen Neulasta Onpro pods, through pharmacy and distributors. A payer, CGM interoperability break or algorithm issue hits essentially all $2.71B.
Competition is why the retention miss matters. Automation is now table stakes, tubeless remains a genuine hardware moat (per daylongs.com, June 2026), but Medtronic MiniMed 780G sells five minute SmartGuard adjustments, Tandem t:slim X2 sells Control-IQ, Tandem Mobi presses patch directly with phone control, and Beta Bionics iLet joins a fastest growing AID category alongside Omnipod 5, MiniMed 780G and Control-IQ (per delveinsight.com, August 2026). Insulet spent $301.10M on R and D in FY2025, a fraction of what diversified giants deploy across pumps, sensors and algorithms. Type 2 is larger, primary care distributed, copay and prior authorization sensitive, and behaviorally heterogeneous. Trading loyal Type 1 pull through for high volume, high churn Type 2 starts only works if onboarding, sampling, sales compensation and customer care fix retention, which is exactly what management said it is now changing.
What would change the view
- U.S. retention proof, then upgrade to buy. Q3 results, expected November 4 (per simplywall.st, October 2026), need U.S. Omnipod reaccelerating toward 20% plus, utilization stabilizing, and international strength at 30% to 32% holding without price concession. Two quarters of that turns $141.10 at 18.27 times forward earnings from a value trap into a compounder discount to the $167.17 target.
- Net income conversion, not just adjusted margin. Operating income of $473.80M must flow to net income above that $418.30M FY2024 peak, with R and D of $301.10M showing leverage and free cash flow above $349.90M funding capex without drawing cash below $716.10M. Until GAAP EPS above $5.78 reappears, the 26.42 times trailing multiple demands perfection the business just told you it cannot guarantee.
The Bull Case
- A tubeless standard compounding from $1.31B to $2.71B Insulet revenues were $1.31B in FY2022, $1.70B in FY2023, $2.07B in FY2024 and $2.71B in FY2025, with revenue growth of 23.5% in the pack, a run no tubed pump has matched at scale. The driver is the Omnipod platform, led by Omnipod 5 with a proprietary AID algorithm embedded in the pod that integrates with third party CGM over Bluetooth, plus Omnipod DASH and the legacy system, sold to end users through the pharmacy channel and distributors from Acton, Massachusetts with 5400 employees. Pharmacy access is the structural edge over Medtronic MiniMed and Tandem t:slim X2 heritage built on durable equipment channels, lower friction to start, easier refills, recurring pod pull through. That momentum continued into 2026 with Omnipod demand strength in the U.S. and abroad exceeding the high end of guidance per investors.insulet.com, August 2026.
- Software-like $1.94B gross profit at 71.1% margin with operating leverage inflecting Gross profit was $1.94B in 2025 at 71.1% gross margin, operating income was $473.80M in FY2025 versus $308.90M in FY2024 versus $220.00M in FY2023 versus $37.60M in FY2022, for 16.2% operating margin and 12.3% profit margin. EBITDA was $489.30M, ROE was 26.0% and ROA was 9.7%. Net income was $247.10M in FY2025 for diluted EPS of $3.48, down from $418.30M in FY2024, yet operating income, operating cash flow of $569.30M and free cash flow of $349.90M versus $296.20M in 2024 all rose, which is the bull tell: factory and pod scale plus price mix are flowing to operating profit even as bottom line GAAP ebbed. No traditional pump maker discloses this blend of razor and razor blade pricing power at 70% plus gross margin.
- A deleveraged balance sheet that self funds growth Total debt fell to $949.20M from $1.38B in 2024, long term debt fell to $930.80M from $1.30B, while stockholders equity rose to $1.52B from $1.21B in 2024 and $732.70M in 2023, assets were $3.19B and liabilities were $1.68B versus $1.88B in 2024. Cash and cash equivalents were $716.10M against that $949.20M total debt load, with operating cash flow of $569.30M covering capital expenditure of $219.40M to leave free cash flow of $349.90M, versus free cash flow of $36.50M in 2023 and negative $38.30M in 2022. Repurchase of capital stock was only $59.60M, so cash is funding capacity and R and D, not financial engineering, a contrast to leveraged medtech rollups.
- A $141.10 washout price for a 20% plus grower Last close was $141.10 on 2026-10-16, versus a 52 week high of $354.88 and 52 week low of $126.40, with 1 year return of negative 55.4% and 5 year return of negative 51.7%. The pack prices that reset at $9.79B market cap, $10.20B enterprise value, trailing P/E of 26.42, forward P/E of 18.27 and EV/EBITDA of 16.59, with analyst target mean of $167.17 and a buy recommendation. In plain terms, the market cut the stock by more than half while revenue rose from $2.07B to $2.71B and operating income rose from $308.90M to $473.80M. Recent tape chatter frames the move as positioning and bargain hunting around a depressed price rather than a new operating break per quiverquant.com, October 2026, with the next verification set for Q3 results on November 4 per simplywall.st, October 2026.
- R and D funded optionality into Type 2 and fully closed loop Research and development expense was $301.10M in FY2025 versus $219.60M in FY2024 versus $205.00M in FY2023, a reinvestment rate rivals cannot match without hurting tubed hardware margins. The pipeline logic is widening the addressable pod population beyond Type 1 into insulin intensive Type 2, new geographies and sensor pairings, with Insulet sharing glucose control progress from its STRIVE pivotal and EVOLUTION 3 work at ADA 2026 per drugdeliverybusiness.com, June 2026. Management is developing a fully closed loop Type 2 system with no carb counting, no bolus button and no manual titration settings, described as completely different from MiniMed and Tandem approaches per medtechdive.com, June 2026, alongside an upgraded Omnipod 5 supporting broader CGM choice including Abbott FreeStyle Libre 3 Plus per linkedin.com, June 2026. If tubeless wins Type 2, the $2.71B base is the starting point, not the ceiling.
The Bear Case
- Crash without repricing, the multiple still demands perfection. At $141.10 on Oct 16, 2026, Insulet sits just above its 52 week low of $126.40 after falling from a 52 week high of $354.88, with a 1 year return of -55.4% and a 5 year return of -51.7%. Yet it still trades at $9.79B market cap, $10.20B enterprise value, 26.42 times trailing earnings, 18.27 times forward earnings and 16.59 times EV to EBITDA. Consensus is still anchored at a $167.17 mean target with a buy recommendation. That is a growth multiple on a stock the market just de rated, so any repeat of the soft Type 2 retention theme discussed after second quarter results (per finance.yahoo.com, Aug 2026) compresses both earnings and the multiple at once.
- Growth stopped converting to profit. SEC EDGAR revenue was $2.71B in FY2025 versus $2.07B in FY2024 and $1.70B in FY2023, and yfinance shows revenue growth of 23.5% year over year. But SEC EDGAR net income was $247.10M in FY2025 versus $418.30M in FY2024 and $206.30M in FY2023, with diluted EPS of $3.48 versus $5.78 in FY2024 and $2.94 in FY2023. Gross profit was $1.94B on $2.71B, a 71.1% gross margin, yet operating margin was only 16.2% and profit margin only 12.3%. Research and development jumped to $301.10M from $219.60M, while operating income of $473.80M was more than offset at the net line. A high gross margin device maker that grows revenue while net income shrinks on a GAAP basis is not scaling, it is spending to stand still.
- One pod, one reimbursement decision, $2.71B at risk. The business summary is Omnipod 5 with an algorithm in the pod linked by Bluetooth to a third party CGM, Omnipod DASH with a Bluetooth pod and handheld controller, and the legacy Omnipod Insulin Management System, plus pods for Amgen for the Neulasta Onpro kit. That is concentration, not diversification, with sales through the pharmacy channel and independent distributors and 5400 employees leveraged to one form factor. Any payer tightening, CGM interoperability break, algorithm recall, or pricing concession hits essentially all revenue, unlike Medtronic or Abbott where diabetes is one division among many.
- Tubeless was a moat, now it is a target. Insulet built ease of use leadership with tubeless wearability, but the chase pack now sells automation, not tubing. Medtronic MiniMed 780G and Tandem t:slim X2 with Control-IQ compete on hybrid closed loop time in range and five minute adjustments, while Tandem Mobi presses directly into patch with a thinner profile and phone control. That intensifying patch race was the explicit theme at ADA 2026, where multiple potential entrants including Beta Bionics, Tandem Diabetes Care and MiniMed were framed as future Omnipod 5 competitors (per drugdeliverybusiness.com, June 2026), in a market described as moderately concentrated across BD, Baxter, Medtronic, Insulet, Tandem and others competing on connectivity and remote monitoring (per grandviewresearch.com, Oct 2026). Insulet spent $301.10M on R and D in FY2025, a fraction of what diversified giants can deploy across pumps, sensors and algorithms.
- Type 2 expansion swaps loyal Type 1s for high churn volume. Management has leaned on Type 2 for new customer starts, but acknowledged weaker than expected early retention and utilization in Type 2, prompting changes to customer care, sales compensation and sampling (per perplexity.ai, Aug 2026) and a cut to the U.S. outlook even as international stayed strong (per finance.yahoo.com, Aug 2026). That matters because Type 2 is primary care distributed, behaviorally heterogeneous, and payer sensitive, sold largely through pharmacy benefit economics where copay, prior authorization and 90 day onboarding determine lifetime value. The balance sheet leaves little room for a leaky bucket: cash of $716.10M versus $953.30M a year earlier, total debt of $949.20M with long term debt of $930.80M, total liabilities of $1.68B against equity of $1.52B on assets of $3.19B, capex of $219.40M against operating cash flow of $569.30M and free cash flow of $349.90M. With 1085 institutions reporting holders and institutionsPercentHeld at 1.06968, a retention miss turns a crowded growth long into forced selling, which the move from $354.88 toward $126.40 already previews.
Key Risks
- 1. One pod, one company: Omnipod concentration makes quality or supply the stock.
- 2. Type 2 bet fails to stick: retention, not starts, decides the next leg of $2.71B revenue growth.
- 3. Tubeless moat narrows: Tandem and Medtronic are coming tubeless.
- 4. Rented ecosystem: Omnipod 5 lives or dies on third party CGM and Bluetooth.
- 5. Growth multiple on fragile earnings: $141.10 still prices perfection after a 55.4% drawdown.
1. Single platform concentration and pod quality
Insulet is Omnipod, with FY2025 Revenues of $2.71B built almost entirely on disposable pods plus a small Drug Delivery tail for Amgen Neulasta Onpro, so a cannula, adhesive, algorithm, or line stoppage is a revenue event, not a warranty footnote. The company runs highly automated production for tens of millions of pods annually with 5400 employees, and the operating leverage shows in $1.94B of gross profit at 71.1% gross margin and $473.80M of operating income at 16.2% operating margin, which is exactly why a field action hurts both sales and that margin stack. A voluntary medical device correction first disclosed in May 2026 across Omnipod 5, DASH and Eros lines remains the live case study (per trefis.com, June 2026), with follow up commentary still discussing manual inspections until automation arrives (per factorstoday.com, September 2026). Unlike Medtronic or Tandem Diabetes Care, which can mix tubed pumps, CGM partnerships, and services, Insulet has no second engine if pods pause.
What would confirm this risk: A new FDA correction, warning letter, import hold, or Acton and Malaysia capacity constraint that cuts U.S. pharmacy fill rates for two consecutive quarters.
2. Type 2 expansion meets retention and payer reality
The bull case after FY2024 Revenues of $2.07B to FY2025 Revenues of $2.71B was Type 2 diabetes, where the addressable pool dwarfs Type 1 but price sensitivity, prior authorization, and persistence are structurally worse. Management flagged lower retention among Type 2 customers and revised U.S. growth expectations while raising international targets, with Q2 described as strong revenue that still exceeded the high end of guidance (per investors.insulet.com, August 2026) but with Type 2 churn as the offset (per finance.yahoo.com, August 2026). That matters because Insulet sells through the pharmacy channel, which lowers upfront friction versus the durable medical equipment gauntlet used by tubed pump rivals, but also makes it easier to quit, and a 23.5% revenue growth print means little if cohorts churn in months 6 to 12. Watch payer mix: broader Type 2 coverage invites utilization management, step edits through smart pens and multiple daily injections, and rebate pressure.
What would confirm this risk: U.S. Omnipod new starts stay strong while net revenue per cohort flattens as Type 2 discontinuance rises and gross to net widens.
3. Tubeless differentiation erodes
Insulet owns tubeless today, Medtronic owns installed base and Tandem owns miniaturization, and the gap is closing as Tandem advances a tubeless Mobi capability and Medtronic advances its Fit patch effort, with a smaller startup patch pipeline also targeting commercialization (per factorstoday.com, September 2026). Insulet was cited as the leader in U.S. and European new customer starts in 2025, yet the same analyses note Tandem Mobi narrowing the form factor advantage (per flash.stocksentinel.ai, August 2026). Competition is not only pumps: smart pens, connected caps, and basal only titration tools compete for Type 2 patients who will not wear a pod every three days. Insulet spent $301.10M on R&D in FY2025, up from $219.60M in FY2024, but Medtronic and Dexcom outspend it in absolute dollars and can bundle pump, CGM, and software.
What would confirm this risk: Tandem or Medtronic wins FDA clearance for a fully tubeless automated delivery patch and takes measurable U.S. new start share within four quarters.
4. Dependence on CGM partners, Bluetooth, and the phone in your pocket
Omnipod 5 embeds its automated insulin delivery algorithm in the pod but still obtains glucose values through wireless Bluetooth communication with a third party continuous glucose monitor, and Omnipod DASH is controlled by a smartphone like manager, so Insulet controls the pod but rents the sensing and connectivity layer. That creates three failure points Insulet does not fully own: CGM accuracy and availability led by Dexcom and Abbott, iOS and Android update cycles, and Bluetooth dropout in the real world. A CGM recall, supply shortage, unfavorable bundling deal with Medtronic or Tandem, or a bad phone OS push can read as an Insulet failure to the patient. With Total Assets of $3.19B and Stockholders Equity of $1.52B, Insulet cannot simply buy its way out of this dependency by building a CGM.
What would confirm this risk: A major CGM partner prioritizes its own or a rival closed loop, degrades Omnipod 5 interoperability, or raises sensor pricing while Insulet absorbs the churn.
5. High expectations, thin and volatile earnings, stretched operations
At $141.10, down from a 52 week high of $354.88 and a 52 week low of $126.40, Insulet has already suffered a 55.4% one year decline, yet still trades at 26.42 times trailing earnings, 18.27 times forward earnings, and 16.59 times EV/EBITDA on a $9.79B market cap and $10.20B enterprise value, versus a $167.17 analyst target mean and a buy recommendation. Profitability is improving at the operating line, with OperatingIncomeLoss of $473.80M in FY2025 versus $308.90M in FY2024, but NetIncomeLoss fell to $247.10M in FY2025 from $418.30M in FY2024, leaving a 12.3% profit margin, 26.0% ROE, and 9.7% ROA that do not leave room for a growth stumble. Cash of $716.10M against Total Debt of $949.20M and Total Liabilities Net Minority Interest of $1.68B is manageable, and FY2025 Operating Cash Flow of $569.30M less Capital Expenditure of $219.40M funds the build, but free cash flow around $236.90M on a trailing basis is thin cover if retention spending, inspections, or litigation step up.
What would confirm this risk: Two quarters of mid teens or lower Omnipod growth with flat to down operating margin, proving the forward multiple was underwriting Type 2 persistence that never arrived.
Lessons
Insulet is a case study in how a simple form factor change compounds when paired with superior distribution, and how the market still reprices it violently. The facts trace to SEC EDGAR annual XBRL and yfinance.
1. Form factor plus pharmacy channel creates the compounding
Own the refill, own the patient. Insulet sells Omnipod 5, Omnipod DASH and the legacy Omnipod Insulin Management System through the pharmacy channel and independent distributors, not just the classic durable medical equipment gauntlet used by Medtronic and Tandem. That choice, plus a tubeless pod that pairs over Bluetooth with third party continuous glucose monitors like Dexcom, turned diabetes hardware into a consumer like refill. SEC EDGAR revenues rose from $1.31B in FY2022 to $2.07B in FY2024 to $2.71B in FY2025, with yfinance logging 23.5% year over year revenue growth. The payoff is visible in yfinance gross margin of 71.1% and operating margin of 16.2%, a profile tubed pump makers struggle to match without the same disposables flywheel. The side business supplying pods to Amgen for the Neulasta Onpro kit proves the platform extends beyond insulin.
2. Separate operating power from GAAP noise
Read operating income first. SEC EDGAR operating income marched from $37.60M in FY2022 to $220.00M in FY2023 to $308.90M in FY2024 to $473.80M in FY2025, while net income spiked then fell from $4.60M to $206.30M to $418.30M to $247.10M over the same years. Diluted EPS tells the same story, falling from $5.78 to $3.48 even as the core got stronger. The lesson for medtech, where debt, taxes and one timers cloud the P and L: underwrite on operating leverage and cash, not the headline EPS print. Here operating cash flow of $569.30M in FY2025 and free cash flow of $349.90M confirm the operating trend that net income obscures.
3. Delever while you invest
Use the high margin to buy freedom. Insulet cut total debt from $1.38B in FY2024 to $949.20M in FY2025 and long term debt from $1.30B to $930.80M, while stockholders equity grew from $1.21B to $1.52B and total assets reached $3.19B against $1.68B of liabilities. At the same time, research and development expense rose from $219.60M to $301.10M, funded internally. Cash fell from $953.30M to $716.10M after that deleveraging and investment, yet free cash flow still improved from $296.20M to $349.90M. With 5400 employees and 1085 institutions on the register, that is how a Healthcare device compounder should behave: shrink the balance sheet risk that kills cyclical peers, keep feeding the algorithm and pod pipeline.
4. No moat protects the multiple
Price for perfection, pay in drawdown. Insulet closed at $141.10 on 2026-10-16, versus a 52 week high of $354.88 and low of $126.40, with a 1 year return of negative 55.4% and 5 year return of negative 51.7%. The business now prints a 12.3% profit margin, 26.0% ROE and 9.7% ROA with a market cap of $9.79B and enterprise value of $10.20B, trading at 26.42 times trailing earnings, 18.27 times forward earnings and 16.59 times EV to EBITDA. Analysts still rate it a buy with a mean target of $167.17. The transferable point: when a razor and blade model is priced like a tech platform, even 23.5% growth plus $236.90M of free cash flow will not stop a greater than 50% peak to trough repricing. Size positions for that volatility.